● Atrial Fibrillation
○ Impact of Atrial Fibrillation
■ It increases a person’s risk of stroke by 4 to 5 times.
■ AFib causes about 25% of ischemic strokes by causing blockage of blood
flow to the brain.
■ AFib doubles the risk of heart-related deaths.
■ The absence of contraction of the atria can result in a loss of cardiac
output anywhere from 15 - 30% due to the absence of an "atrial kick,"
contributing to heart failure.
○ Risk Factors
■ Advancing age*
■ High blood pressure*
■ Coronary artery disease*
■ Cardiomyopathy
■ Obesity
■ European ancestry
■ Athletes
■ Diabetes
■ Heart failure
■ Hyperthyroidism
■ Chronic kidney disease
■ Heavy alcohol use
■ Rheumatic heart disease
■ Valvular heart disease
■ Enlargement of the chambers on the left side of the heart
■ Pericarditis/myocarditis
■ Sleep Apnea
○ Valvular vs Non-Valvular AFib
■ Valvular: AF in the presence of moderate-to-severe mitral stenosis
(potentially requiring surgical intervention) or in the presence of an
artificial (mechanical) heart valve
■ Non-valvular: AF in the absence of moderate-to-severe mitral stenosis or
a mechanical heart valve
○ Clinical Presentation
■ Many people do not experience any symptoms and are unaware of their
diagnosis – Sometimes it is an incidental finding upon examination
■ Symptomatic presentation:
● General fatigue
● Rapid and irregular heartbeat
● Fluttering or “thumping” in the chest
● Dizziness
● Shortness of breath and anxiety
● Weakness
● Faintness or confusion
, ● Fatigue when exercising
● Sweating
● *Chest pain or pressure- (Call 911)
○ Physical Exam
■ On PE: Irregular heart rhythm – this is the hallmark finding of AFib,
tachycardia (typically 110s-140s), hypotension
■ Possible findings in someone with AF include:
● JVD, rales or effusions from HF
● Murmurs suggest stenosis or regurgitation.
● LE edema (HF or DVT),
● Exophthalmia (*bulging eyes)
● Signs of stroke, including facial droop, arm weakness, and slurred
speech
■ Possible PE findings correspond with diseases coexisting with AF or
being high risk for AF rather than the disease presentation itself
○ EKG
■ There are no visible P waves (no measurable PR interval) & an irregularly
irregular QRS complex. The ventricular rate is frequently fast.
■ *GOLD standard
■
■
○ Classifying AFib
■ Paroxysmal AF
● AF that terminates spontaneously or with intervention within 7
days of onset
● Episodes may recur with variable frequency
■ Persistent AF
, ● Continuous AF that is sustained >7 days
■ Long-standing persistent AF
● Continuous AF >12 months in duration
■ Permanent AF
● The term “permanent AF” is used when the patient & clinician
decide to stop further attempts to restore &/or maintain sinus
rhythm.
● Acceptance of AF represents a therapeutic attitude on the part of
the patient and clinician rather than an inherent pathophysiological
attribute of AF
● Acceptance of AF may change as symptoms, efficacy of
therapeutic interventions, & patient & clinician preferences evolve.
■ Nonvalvular AF
● AF in the absence of rheumatic mitral stenosis, a mechanical or
bioprosthetic heart valve, or mitral valve repair.
○ Labs
■ CBC
■ CMP
■ TSH
■ BNP
■ PT/PTT/INR
○ Other Diagnostic Tests
■ Echocardiogram - evaluation of size & function of atria & ventricles;
detection of valvular heart disease, left ventricular hypertrophy, &
pericardial disease.
■ Transesophageal Echocardiogram (TEE) - the most sensitive & specific
technique to detect LA thrombi.
■ Event Recorders (Implantable loop recorders, Holter monitors) -
identify arrhythmia if intermittent, correlate symptoms, or use rate control
strategies
■ Stress test
■ EP study
○ Management
■ Goals of Treatment for AF
● Prevention of Thromboembolism – utilize the Chadsvasc score
to determine stroke risk
● Rate Control (preferred over rhythm control)
○ Beta-Adrenergic Receptor Blockers
■ atenolol, metoprolol, nadolol, propranolol, & sotalol
○ Nondihydropyridine Calcium Channel Blockers
■ diltiazem and verapamil
○ Digitalis Glycoside
■ Digoxin
● Rhythm Control
, ○ for patients who don’t tolerate loss of atrial kick
(hemodynamic instability):
■ Synchronized cardioversion
■ Pharmacologic cardioversion: dofetilide, flecainide,
propafenone, ibutilide, or amiodarone (consider
long half-life, pulmonary toxicity, thyroid
dysfunction)
■ Chadsvasc - To determine stroke risk
●
●
■ Anticoagulation
● Vit K antagonist
○ Warfarin (serum monitoring: goal INR 2-3)
● Direct Thrombin Inhibitor
○ Dabigatran (Pradaxa) - 150 mg PO BID (no serum
monitoring)
● Factor Xa Inhibitors
○ Rivaroxaban, Edoxaban, & Apixaban (no serum
monitoring)
○ Xarelto (Rivaroxaban) - 20 mg PO QD
■ (if switching from warfarin to Xarelto, d/c warfarin &
start Xarelto when INR < 3)
○ Eliquis (Apixaban) - 5 mg PO BID
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller YourAssignmentHandlers. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $14.99. You're not tied to anything after your purchase.